Skip to main content
. 2020 May 31;37(6):114. doi: 10.1007/s11095-020-02816-w

Fig. 3.

Fig. 3

Charge variant assessment of infliximab (EU), ABP 710, and infliximab (US) by CEX-HPLC. (a) Untreated; (b) carboxypeptidase B digested.